https://orcid.org/0000-0002-9046-5666
References
- Randle E, Ninis N, Inwald D. Invasive pneumococcal disease. Arch Dis Child Educ Pract Ed. 2011;96(5):183–190.
- Wantuch PL, Avci FY. Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them. Hum Vaccin Immunother. 2018;14(9):2303–2309.
- van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One. 2012;7(7):e39150.
- Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis. 2010;51(6):692–699.
- van Aalst M, Lötsch F, Spijker R, et al. Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis. Travel Med Infect Dis. 2018;24:89–100.
- World Health Organisation. Pneumococcal disease; [ cited 2019 Oct 9]. Available from: https://www.who.int/ith/diseases/pneumococcal/en/
- von Mollendorf C, von Gottberg A, Tempia S, et al.; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Increased risk for and mortality from invasive pneumococcal disease in HIV-exposed but uninfected infants aged <1 year in South Africa, 2009-2013. Clin Infect Dis. 2015;60(9):1346–1356.
- Garrouste-Orgeas M, Azoulay E, Ruckly S, et al. Diabetes was the only comorbid condition associated with mortality of invasive pneumococcal infection in ICU patients: a multicenter observational study from the Outcomerea research group. Infection. 2018;46(5):669–677.
- Hughes GJ, Wright LB, Chapman KE, et al. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiol Infect. 2016;144(12):2654–2669.
- Kim JH, Baik SH, Chun BC, et al. Adult invasive pneumococcal disease in the Republic of Korea: risk medical conditions and mortality stratified by age group. Int J Infect Dis. 2018;74:136–144.
- Beatty JA, Majumdar SR, Tyrrell GJ, et al. Prognostic factors associated with mortality and major in-hospital complications in patients with bacteremic pneumococcal pneumonia: population-based study. Medicine (Baltimore). 2016;95(46):e5179.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–94.
- Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses; [ cited 2019 Oct 9]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
- Higgins JPT. Thompson SG: quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
- Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–129.
- Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
- Sousa A, Pérez-Rodríguez MT, Nodar A, et al. Clinical and microbiological characteristics of unusual manifestations of invasive pneumococcal disease. Enferm Infecc Microbiol Clin. 2018;36(5):284–289.
- Marrie TJ, Tyrrell GJ, Majumdar SR, et al. Effect of age on the manifestations and outcomes of invasive pneumococcal disease in adults. Am J Med. 2018;131(1):100.e1-100.e7.
- Floeystad HK, Holm A, Sandvik L, et al. Increased long-term mortality after survival of invasive pneumococcal disease: a population-based study. Infect Dis (Lond). 2017;49(5):365–372.
- Grau I, Ardanuy C, Calatayud L, et al. Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections. Int J Infect Dis. 2014;25:59–64.
- Singleton RJ, Butler JC, Bulkow LR, et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine. 2007;25(12):2288–2295.
- Lee HY, Wu TL, Su LH, et al. Invasive pneumococcal disease caused by ceftriaxone-resistant Streptococcus pneumoniae in Taiwan. J Microbiol Immunol Infect. 2018;51(4):500–509.
- Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422. DOI:https://doi.org/10.1002/14651858.CD000422.pub3
- Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis. 2009;49(2):e23–9.